Document resource
Recent advances in neurodegenerative biomarker research shed light on beta-synuclein as a promising indicator of synaptic dysfunction in Alzheimer’s disease (AD) and related dementias. Two noteworthy studies—Barba et al 1 and Kong and Jung2—independently demonstrate that serum beta-synuclein levels are significantly associated with clinical staging and synaptic degeneration. Barba et al 1 showed that beta-synuclein levels progressively increase across the AD continuum, from preclinical to mild cognitive impairment and dementia, supporting its role as a marker of disease severity. This cross-sectional pattern provides a foundation for understanding beta-synuclein’s potential as a staging biomarker.